Kuanhou H. Mou

277 West Yanta Road
Xi'an, 710061, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 29 publications

Increased antioxidant levels favour psoriasis risk reduction in specific populations: a cross-sectional study based on National Health and Nutrition Examination Survey (NHANES).

Increased antioxidant levels favour psoriasis risk reduction in specific populations: a cross-sectional study based on National Health and Nutrition Examination Survey (NHANES).

Journal: The British journal of nutrition

Published: January 02, 2026

A MXene nanoplatform for psoriasis therapy: Synergistic scavenging of ROS and cfDNA to target inflammation and proliferation.

A MXene nanoplatform for psoriasis therapy: Synergistic scavenging of ROS and cfDNA to target inflammation and proliferation.

Journal: Free radical biology & medicine

Published: December 01, 2025

Can we navigate the pitfalls of tofacitinib randomized controlled trials in vitiligo? Addressing long-term safety and generalizability for enhanced clinical translation.

Can we navigate the pitfalls of tofacitinib randomized controlled trials in vitiligo? Addressing long-term safety and generalizability for enhanced clinical translation.

Journal: Journal of the American Academy of Dermatology

Published: October 12, 2025

Melanoma vaccines: current R&D landscape, translational hurdles, and future outlook-a perspective drawn from 442 clinical trials.

Melanoma vaccines: current R&D landscape, translational hurdles, and future outlook-a perspective drawn from 442 clinical trials.

Journal: Frontiers in immunology

Published: September 03, 2025

SYHX1901, an oral dual Janus kinase and spleen tyrosine kinase inhibitor, for moderate-to-severe plaque psoriasis: A randomized phase 2 trial.

SYHX1901, an oral dual Janus kinase and spleen tyrosine kinase inhibitor, for moderate-to-severe plaque psoriasis: A randomized phase 2 trial.

Journal: Journal of the American Academy of Dermatology

Published: May 18, 2025

Kimura disease: Successful treatment with dupilumab.

Kimura disease: Successful treatment with dupilumab.

Journal: Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG

Published: December 04, 2024

Landscapes of gut microbiome and metabolic signatures in vitiligo patients with co-morbid emotional distress.

Landscapes of gut microbiome and metabolic signatures in vitiligo patients with co-morbid emotional distress.

Journal: Journal of dermatological science

Published: November 08, 2024

Efficacy and safety of vunakizumab in moderate-to-severe chronic plaque psoriasis: A randomized, double-blind, placebo-controlled phase 3 trial.

Efficacy and safety of vunakizumab in moderate-to-severe chronic plaque psoriasis: A randomized, double-blind, placebo-controlled phase 3 trial.

Journal: Journal of the American Academy of Dermatology

Published: May 03, 2024

Knowledge, attitude, and practice of psoriatic arthritis among patients with psoriasis.

Knowledge, attitude, and practice of psoriatic arthritis among patients with psoriasis.

Journal: Frontiers in medicine

Published: February 06, 2024

Single-cell transcriptomics reveals peripheral immune responses in non-segmental vitiligo.

Single-cell transcriptomics reveals peripheral immune responses in non-segmental vitiligo.

Journal: Frontiers in immunology

Published: May 12, 2023

PARP1 Is a Prognostic Marker and Targets NFATc2 to Promote Carcinogenesis in Melanoma.

PARP1 Is a Prognostic Marker and Targets NFATc2 to Promote Carcinogenesis in Melanoma.

Journal: Genetic testing and molecular biomarkers

Published: November 17, 2022

Metagenomic sequencing reveals altered gut microbial compositions and gene functions in patients with non-segmental vitiligo.

Metagenomic sequencing reveals altered gut microbial compositions and gene functions in patients with non-segmental vitiligo.

Journal: BMC microbiology

Published: November 15, 2022

Showing 1-12 of 29

Last Updated: 09/26/2026